Fluoxetine treatment for weight reduction in steroid-induced obesity: A pilot study in myasthenia gravis patients

European Neuropsychopharmacology

Volumn 9, Issue 1-2, 1999, Pages 111-113

  Achiron, Anat ^a   Barak, Yoram ^b   Noy, Shlomo ^a   Pinhas Hamiel, Orit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Abarbanel Medical Center   (Israel)

Author keywords

Fluoxetine; Myasthenia gravis; Obesity; Steroids; Weight loss

Indexed keywords

FLUOXETINE; STEROID;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INSOMNIA; LABORATORY TEST; MALE; MUSCLE FATIGUE; MUSCLE STRENGTH; MYASTHENIA GRAVIS; NAUSEA; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BODY MASS INDEX; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; MUSCLE FATIGUE; MYASTHENIA GRAVIS; OBESITY; PILOT PROJECTS; STEROIDS; WEIGHT LOSS;

EID: 0032969733     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(98)00012-1     Document Type: Article

References (23)

1. Barak, Y., Lampl, Y., Achiron, A., Sarova-Pinhas, I., Elizur, A., 1995. Fluoxetine induced weight loss: A pilot study in pospartum women. Isr. J. Psychiatry 32, 51-54.
2. Bray, G., 1985. Complications of obesity. Ann. Intern. Med. 103, 1052-1061.
3. Bray, G.A., 1992. An approach to the classification and evaluation of obesity. In: Bray, G.A., Bjorntorp, P., Brodoff, B.N. (Eds). Obesity, first ed. Lippincott, Philadelphia, pp. 300-301.
4. Bross, R., Hoffer, L.J., 1995. Fluoxentine increases resting energy expenditure and basal body temperature in humans. Am. J. Clin. Nutr. 61, 1020-1025.
5. Brownell, K.D., 1982. Obesity: understanding and treating a serious, prevalent and refractory disorder. J. Consult. Clin. Psychol. 50, 820-840.
6. Darga, L.L., Carroll-Michals, L., Botsford, S.J., Lucas, C.P., 1991. Fluoxetine's effects on weight loss in obese subjects. Am. J. Clin. Nutr. 54, 321-325.
7. Ferguson, J.M., Feighner, J.P., 1987. Fluoxetine-induced weight loss in overweight non-depressed humans. Int. J. Obes 11, 163-170.
8. Goldstein, D.J., Rampey, H.H., Enas, G.G., Potvin, J.H., Fludzinski, L.A., Levine, L.R., 1994. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int. J. Obes. Relat. Metab. Disord. 18, 129-135.
9. Goldstein, D.J., Hanilton, S.H., Masica, D.N., Beasley, C.M., 1997. Fluoxetine in medically stable depressed geriatric patients: Effect on weight. J. Clin. Psychopharmacol. 17, 365-369.
10. Holman, S.L., Goldstein, D.J., Enas, G.G., 1994. Pattern analysis method for assessing successful weight reduction. Int. J. Obes. Relat. Metab. Disord. 18, 281-285.
11. Levine, L.R., Rosenblatt, S., Bosmworth, J., 1987. Use of a serotonin reuptake inhibitor, fluoxetine, in the treatment of obesity. Int. J. Obes. 11, 185-190.
12. Moses, P.L., Wurtman, R.J., 1984. Suppression of appetite and reduction of body weight in normal and obese mice by fluoxetine, a selective inhibitor of serotonin uptake. Fed. Proc. 44, 1162-1166.
13. O'Kane, M., Wiles, P.G., Wales, J.K., 1994. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabetic Med. 11, 105-110.
14. Pascuzzi, R.M., Coslett, H.B., Johns, T.R., 1984. Myasthenia gravis treatment with long term corticosteroid. A report of mysthenia gravis cases. Ann. Neurol. 15, 291-298.
15. Plotz, C.M., Knowlton, A.I., Ragan, C., 1952. The natural history of Cushing's syndrome. Am. J. Med. 13, 597-614.
16. Ross, E.J., Marshall-Jones, P., Freedman, M., 1966. Cushing's syndrome: diagnostic criteria. Q. J. Med. 35, 149-162.
17. Ross, E.J., Linch, D.C., 1982. Cushing's syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet ii, 646-649.
18. Sanders, D.B., Scoppetta, C., 1994. The treatment of patients with myasthenia gravis. Neurol. Clin. 12, 343-368.
19. Scheen, A.J., Desaive, C., Lefebvre, P.J., 1994. Therapy for obesity -today and tomorrow. Baillieres Clin. Endocrinol. Metab. 8, 705-727.
20. Van Itallie, T.B., 1985. Health implications of overweight and obesity in the United States. Ann. Intern. Med. 103, 983-988.
21. Wadden, T.A., Stunkard, A.J., 1985. Social and psychological consequences of obesity. Ann. Intern. Med. 103, 1062-1067.
22. Wurtman, J.J., Wurtman, R.J., 1977. Fenfluramine and fluoxetine spare protein consumption while suppressing caloric intake by rats. Science 198, 1178-1180.
23. Zerbe, R.L., 1987. Safety of fluoxetine in the treatment of obesity. Int. J. Obes. 11, 191.